The European biosimilar market is the undisputed global leader, currently holding over 50% of the market share worldwide and valued at over $16 billion
As a pharmaceutical blogger focused on biologics, I’ve been watching this space evolve from a cost-containment experiment into a sophisticated, high-growth engine for the entire continent. For 2026 and beyond, the narrative is shifting from simple adoption to complex market dynamics driven by policy reform, patent cliffs, and geographic specialization.
The Big Picture: A Market in Transition
The numbers are staggering. The global biosimilar market is projected to grow at a CAGR of nearly 23% through 2034, with Europe acting as the primary catalyst
. This growth is fueled by the “patent cliff”—nearly 100 biologics are set to lose patent protection in the EU by 2032 . However, a critical detail often overlooked is the pipeline gap. According to a recent report cited by Pulse News, a staggering 79% of these soon-to-be off-patent biologics currently have no biosimilars under development . This represents a potential opportunity loss of $143 billion and highlights that the “low-hanging fruit” has largely been picked. The future competition will be in niche therapeutic areas like ophthalmology and dermatology, where adoption curves are slower but the need is immense
.
EU Market Leadership: A Country-by-Country Breakdown
While the European Medicines Agency (EMA) provides a centralized approval pathway, the commercial reality varies dramatically by member state. The market is not a monolith; it’s a collection of distinct access environments.
Italy: The Unlikely Champion
In 2025, Italy holds the largest share of the European biosimilar market at 20.8%
. This dominance is driven by a high burden of chronic disease—affecting nearly 24 million Italians—coupled with aggressive government policies that incentivize biosimilar prescription to curb healthcare spending
.
Germany & France: The Volume Drivers
As the largest pharma markets in Europe, Germany and France remain pivotal. Their well-established healthcare systems and supportive reimbursement frameworks ensure high patient access and rapid uptake post-launch
.
United Kingdom & Spain: The Fast Followers
Post-Brexit, the UK (via the MHRA) has maintained alignment with EMA guidelines, ensuring a steady flow of biosimilars. Spain, alongside Italy, has been a leader in implementing regional health policies that promote biosimilar utilization in hospitals.
Production Powerhouse: Where Are Biosimilars Made?
Understanding where these complex molecules are manufactured is just as important as knowing where they are sold. Europe is not just a consumer; it is a critical node in the global manufacturing network.
Poland (The Rising Hub): A significant development occurred in February 2026, when Rezon Bio’s Warsaw-Duchnice facility received FDA approval for commercial biosimilar manufacturing, having already secured EMA GMP certification for European supply
. This dual certification positions Poland as a strategic bridge between EU and US markets, offering reliable, high-quality contract development and manufacturing (CDMO) services.
Germany & Western Europe: Traditional powerhouses remain central to in-house manufacturing for giants like Novartis (Sandoz), Pfizer, and Merck, who prefer full control over production to ensure quality and regulatory compliance
.
The Korean Influence: It is impossible to discuss European production without acknowledging external players. In 2024, South Korean firms (like Samsung Bioepis and Celltrion) developed 12 of the 28 biosimilars that received EMA marketing authorization recommendations—the highest share by any single country
. While manufacturing often occurs in Asia, these products are tailored specifically for the European market.
Regulatory Tailwinds: The “Bolar Exemption” and Beyond
The biggest news for market access in 2026 is the provisional agreement on the comprehensive reform of EU Pharmaceutical Legislation
.
The game-changer is the expansion of the “Bolar Exemption.” This now allows biosimilar manufacturers to engage in Health Technology Assessment (HTA) and pricing negotiations while the reference product is still under patent protection
. This ensures “day-one” launch readiness the moment exclusivity expires. This shift from a sequential to a parallel process will drastically shorten the revenue exclusivity window for originators and speed up patient access to affordable biologics
.
The Road Ahead: Challenges and Strategic Imperatives
As we move through 2026, success in the EU biosimilar market will require more than just a “me-too” product at a discount.
Differentiation is Key: As noted in the Korea report, factors like formulation convenience (e.g., pre-filled pens vs. vials) and physician familiarity are now critical drivers of real-world uptake, sometimes outweighing pure price advantages
Niche Expansion: While autoimmune diseases (led by infliximab) dominate currently, the next wave will target ophthalmology (e.g., ranibizumab) and dermatology, where market education is still needed
Supply Chain Resilience: With the EU pushing for the Critical Medicines Act, there is a growing emphasis on localizing production to avoid shortages. This could lead to more “Made in Europe” mandates, benefiting CDMOs like Rezon Bio in Poland
The European biosimilar market is maturing, but its growth trajectory remains explosive. For industry watchers, the focus must shift from whether biosimilars will penetrate the market to how quickly they can navigate the new regulatory landscape and where they will be manufactured to meet both EU and global demand.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
